{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:11:04Z","timestamp":1793772664753,"version":"4.6.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"German Federal Ministry of Education and Research","award":["PD dementia"],"award-info":[{"award-number":["PD dementia"]}]},{"name":"German Federal Ministry of Education and Research","award":["FKZ 031L0137B"],"award-info":[{"award-number":["FKZ 031L0137B"]}]},{"DOI":"10.13039\/501100005224","name":"Deutsches Zentrum f\u00fcr Neurodegenerative Erkrankungen","doi-asserted-by":"publisher","award":["MIGAP study"],"award-info":[{"award-number":["MIGAP study"]}],"id":[{"id":"10.13039\/501100005224","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente"],"award-info":[{"award-number":["Ricerca Corrente"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"DOI":"10.1038\/s41531-025-01221-7","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T04:36:28Z","timestamp":1764563788000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Quantification of cerebrospinal fluid \u03b1-synuclein seeds by endpoint dilution seed amplification assay in Parkinson\u2019s disease"],"prefix":"10.1038","volume":"12","author":[{"given":"Kathrin","family":"Brockmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Ticca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Lerche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mastrangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Mammana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Wurster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Vittoriosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Roeben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Kathrin","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Deuschle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Baiardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Parchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"1221_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00401-020-02160-8","volume":"140","author":"M Rossi","year":"2020","unstructured":"Rossi, M. et al. Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathol. 140, 49\u201362 (2020).","journal-title":"Acta Neuropathol."},{"key":"1221_CR2","doi-asserted-by":"publisher","first-page":"e1944","DOI":"10.1212\/WNL.0000000000207147","volume":"100","author":"A Iranzo","year":"2023","unstructured":"Iranzo, A. et al. Misfolded \u03b1-synuclein assessment in the skin and CSF by RT-QuIC in isolated REM sleep behavior disorder. Neurology 100, e1944\u2013e1954 (2023).","journal-title":"Neurology"},{"key":"1221_CR3","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1038\/s41591-023-02450-0","volume":"29","author":"S Palmqvist","year":"2023","unstructured":"Palmqvist, S. et al. Cognitive effects of Lewy body pathology in clinically unimpaired individuals. Nat. Med. 29, 1971\u20131978 (2023).","journal-title":"Nat. Med."},{"key":"1221_CR4","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","volume":"22","author":"A Siderowf","year":"2023","unstructured":"Siderowf, A. et al. Assessment of heterogeneity among participants in the Parkinson\u2019s Progression Markers Initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 22, 407\u2013417 (2023).","journal-title":"Lancet Neurol."},{"key":"1221_CR5","first-page":"1","volume":"78","author":"Z Wang","year":"2020","unstructured":"Wang, Z. et al. Skin \u03b1-synuclein aggregation seeding activity as a novel biomarker for Parkinson's disease. JAMA Neurol. 78, 1\u201311 (2020).","journal-title":"JAMA Neurol."},{"key":"1221_CR6","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","volume":"23","author":"T Simuni","year":"2024","unstructured":"Simuni, T. et al. A biological definition of neuronal \u03b1-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 23, 178\u2013190 (2024).","journal-title":"Lancet Neurol."},{"key":"1221_CR7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","volume":"23","author":"GU H\u00f6glinger","year":"2024","unstructured":"H\u00f6glinger, G. U. et al. A biological classification of Parkinson\u2019s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol. 23, 191\u2013204 (2024).","journal-title":"Lancet Neurol."},{"key":"1221_CR8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00401-023-02663-0","volume":"147","author":"GM Bentivenga","year":"2024","unstructured":"Bentivenga, G. M. et al. Performance of a seed amplification assay for misfolded alpha-synuclein in cerebrospinal fluid and brain tissue in relation to Lewy body disease stage and pathology burden. Acta Neuropathol. 147, 18 (2024).","journal-title":"Acta Neuropathol."},{"key":"1221_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41531-023-00627-5","volume":"10","author":"K Brockmann","year":"2024","unstructured":"Brockmann, K. et al. CSF \u03b1-synuclein seed amplification kinetic profiles are associated with cognitive decline in Parkinson\u2019s disease. NPJ Park Dis. 10, 24 (2024).","journal-title":"NPJ Park Dis."},{"key":"1221_CR10","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1093\/brain\/awae405","volume":"148","author":"A Mastrangelo","year":"2025","unstructured":"Mastrangelo, A. et al. Alpha-synuclein seed amplification assay longitudinal outcomes in Lewy body disease spectrum. Brain 148, 2038\u20132048 (2025).","journal-title":"Brain"},{"key":"1221_CR11","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000210279","volume":"104","author":"DG Coughlin","year":"2025","unstructured":"Coughlin, D. G. et al. \u03b1-synuclein seed amplification assay, amplification parameters and the risk of progression in prodromal Parkinson disease. Neurology 104, e210279 (2025).","journal-title":"Neurology"},{"key":"1221_CR12","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1515\/cclm-2023-1472","volume":"62","author":"A Mammana","year":"2024","unstructured":"Mammana, A. et al. Improving protocols for \u03b1-synuclein seed amplification assays: analysis of preanalytical and analytical variables and identification of candidate parameters for seed quantification. Clin. Chem. Lab Med. 62, 2001\u20132010 (2024).","journal-title":"Clin. Chem. Lab Med."},{"key":"1221_CR13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13024-023-00613-8","volume":"18","author":"G Bellomo","year":"2023","unstructured":"Bellomo, G. et al. Cerebrospinal fluid lipoproteins inhibit \u03b1-synuclein aggregation by interacting with oligomeric species in seed amplification assays. Mol. Neurodegener. 18, 20 (2023).","journal-title":"Mol. Neurodegener."},{"key":"1221_CR14","doi-asserted-by":"publisher","first-page":"e1012554","DOI":"10.1371\/journal.ppat.1012554","volume":"20","author":"A Srivastava","year":"2024","unstructured":"Srivastava, A. et al. Enhanced quantitation of pathological \u03b1-synuclein in patient biospecimens by RT-QuIC seed amplification assays. PLoS Pathog. 20, e1012554 (2024).","journal-title":"PLoS Pathog."},{"key":"1221_CR15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00401-025-02853-y","volume":"149","author":"AM Bernhardt","year":"2025","unstructured":"Bernhardt, A. M. et al. A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for Parkinson\u2019s disease. Acta Neuropathol. 149, 20 (2025).","journal-title":"Acta Neuropathol."},{"key":"1221_CR16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00401-025-02904-4","volume":"149","author":"A Mastrangelo","year":"2025","unstructured":"Mastrangelo, A. et al. Quantification of Lewy body pathology by cerebrospinal fluid endpoint dilution RT-QuIC in a neuropathological autopsy cohort of clinically heterogeneous participants. Acta Neuropathol. 149, 67 (2025).","journal-title":"Acta Neuropathol."},{"key":"1221_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14528","volume":"21","author":"A Leuzy","year":"2025","unstructured":"Leuzy, A. et al. Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer\u2019s disease. Alzheimers Dement 21, e14528 (2025).","journal-title":"Alzheimers Dement"},{"key":"1221_CR18","doi-asserted-by":"publisher","first-page":"e1137","DOI":"10.1212\/WNL.0000000000200040","volume":"98","author":"N Mattsson-Carlgren","year":"2022","unstructured":"Mattsson-Carlgren, N. et al. Cerebrospinal fluid biomarkers in autopsy-confirmed Alzheimer disease and frontotemporal lobar degeneration. Neurology 98, e1137\u2013e1150 (2022).","journal-title":"Neurology"},{"key":"1221_CR19","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/brain\/awab431","volume":"145","author":"I Poggiolini","year":"2022","unstructured":"Poggiolini, I. et al. Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. Brain 145, 584\u2013595 (2022).","journal-title":"Brain"},{"key":"1221_CR20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s40478-021-01282-8","volume":"9","author":"MJ Russo","year":"2021","unstructured":"Russo, M. J. et al. High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson\u2019s disease. Acta Neuropathol. Commun. 9, 179 (2021).","journal-title":"Acta Neuropathol. Commun."},{"key":"1221_CR21","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/mds.27646","volume":"34","author":"UJ Kang","year":"2019","unstructured":"Kang, U. J. et al. Comparative study of cerebrospinal fluid \u03b1-synuclein seeding aggregation assays for diagnosis of Parkinson\u2019s disease. Mov. Disord. 34, 536\u2013544 (2019).","journal-title":"Mov. Disord."},{"key":"1221_CR22","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/mds.10459","volume":"18","author":"I Litvan","year":"2003","unstructured":"Litvan, I. et al. Movement disorders society scientific issues committee report: SIC task force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov. Disord. 18, 467\u2013486 (2003).","journal-title":"Mov. Disord."},{"key":"1221_CR23","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/mds.20213","volume":"19","author":"CG Goetz","year":"2004","unstructured":"Goetz, C. G. et al. Movement disorder society task force report on the Hoehn and Yahr staging scale: status and recommendations. Mov. Disord. 19, 1020\u20131028 (2004).","journal-title":"Mov. Disord."},{"key":"1221_CR24","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz, C. G. et al. Movement disorder society-sponsored revision of the unified Parkinson\u2019s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 23, 2129\u20132170 (2008).","journal-title":"Mov. Disord."},{"key":"1221_CR25","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/mds.20844","volume":"21","author":"KR Chaudhuri","year":"2006","unstructured":"Chaudhuri, K. R. et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson\u2019s disease: the NMSQuest study. Mov. Disord. 21, 916\u2013923 (2006).","journal-title":"Mov. Disord."},{"key":"1221_CR26","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1212\/WNL.0b013e3181c34b47","volume":"73","author":"S Hoops","year":"2009","unstructured":"Hoops, S. et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 73, 1738\u20131745 (2009).","journal-title":"Neurology"},{"key":"1221_CR27","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein, M. F., Folstein, S. E. & McHugh, P. R. Mini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189\u2013198 (1975).","journal-title":"J. Psychiatr. Res."},{"key":"1221_CR28","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1111\/jgs.14779","volume":"65","author":"D Bergeron","year":"2017","unstructured":"Bergeron, D. et al. Multicenter validation of an MMSE-MoCA conversion table. J. Am. Geriatr. Soc. 65, 1067\u20131072 (2017).","journal-title":"J. Am. Geriatr. Soc."},{"key":"1221_CR29","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/mds.27884","volume":"35","author":"S Lerche","year":"2020","unstructured":"Lerche, S. et al. Parkinson\u2019s disease: glucocerebrosidase 1 mutation severity is associated with CSF alpha-synuclein profiles. Mov. Disord. 35, 495\u2013499 (2020).","journal-title":"Mov. Disord."},{"key":"1221_CR30","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1038\/s41591-023-02449-7","volume":"29","author":"C Quadalti","year":"2023","unstructured":"Quadalti, C. et al. Clinical effects of Lewy body pathology in cognitively impaired individuals. Nat. Med. 29, 1964\u20131970 (2023).","journal-title":"Nat. Med."},{"key":"1221_CR31","doi-asserted-by":"publisher","first-page":"e1009480","DOI":"10.1371\/journal.pcbi.1009480","volume":"17","author":"D Cresta","year":"2021","unstructured":"Cresta, D. et al. Time to revisit the endpoint dilution assay and to replace the TCID50 as a measure of a virus sample\u2019s infection concentration. PLoS Comput. Biol. 17, e1009480 (2021).","journal-title":"PLoS Comput. Biol."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01221-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01221-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01221-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T15:04:55Z","timestamp":1767711895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01221-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1221"],"URL":"https:\/\/doi.org\/10.1038\/s41531-025-01221-7","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"assertion":[{"value":"28 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}